Skip to main content

Table 3 Molecular analysis of crawling-type adenocarcinomas (CRAs) and conventional differentiated adenocarcinomas (CDAs)

From: Analysis of clinicopathological and molecular features of crawling-type gastric adenocarcinoma

  CRA (%) CDA (%) P-value
Total (lesions) 51 (100.0) 126 (100.0)  
TP53 gene mutation    <  0.01
 Positive 19 (37.3) 10 (7.9)  
 Negative 32 (62.7) 116 (92.1)  
KRAS gene mutation    0.09
 Positive 0 (0.0) 7 (5.6)  
 Negative 51 (100.0) 119 (94.4)  
BRAF gene mutation    0.64
 Positive 1 (2.0) 0 (0.0)  
 Negative 50 (98.0) 126 (100.0)  
Microsatellite stability status    0.59
 Microsatellite instability (MSI) 5 (9.8) 16 (12.7)  
 Microsatellite stable (MSS) 46 (90.2) 110 (87.3)  
DNA methylation statusa    <  0.01
 High methylated epigenotype 6/45 (13.3) 32 (25.4)  
 Intermediate methylated epigenotype 12/45 (26.7)* 64 (50.8)*  
 Low methylated epigenotype 27/45 (60.0)** 30 (23.8)**  
MLH-1 methylation status    0.03
 Hypermethylated 1 (2.0) 16 (12.7)  
 No hypermethylation 50 (98.0) 110 (87.3)  
Allelic imbalancesa
 1p 17/43 (39.5) 10/93 (10.8) <  0.01
 3p 9/37 (24.3) 17/104 (16.3) 0.28
 4p 17/36 (47.2) 15/111 (13.5) <  0.01
 5q 17/44 (38.6) 31/110 (28.2) 0.21
 8p 16/25 (64.0) 20/105 (19.0) <  0.01
 9p 10/23 (43.5) 18/103 (17.5) <  0.01
 13q 4/12 (33.3) 13/75 (17.3) 0.19
 17p (TP53) 10/34 (29.4) 29/94 (30.9) 0.95
 18q 21/48 (43.8) 18/112 (16.1) <  0.01
 22q 12/23 (52.2) 20/110 (18.2) < 0.01
  1. a Positive number/informative case (%) in DNA methylation status and allelic imbalances
  2. P-values < 0.05 are in bold text
  3. *, p < 0.05; **, p < 0.01